Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Super-sensitive detection of Alzheimer’s disease biomarkers in plasma by an innovative droplet split-and-stack approach

SensApp

The detection of biomarkers in body fluids is of great importance for disease early diagnosis. The clinical practice uses typically immunoassay methods (e.g. ELISA, Enzyme-Linked Immuno Sorbent Assay, and related techniques) for biomarker determination. Unfortunately, these techniques fail dramatically in a wide variety of cases where the...

Funding Programme
Start Date
End Date
Total Funding
€ 3 287 563
European Countries Involved

Support, Monitoring and Reminder Technology for Mild Dementia

SMART4MD

As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of...

Funding Programme
Start Date
End Date
Total Funding
€ 3 834 555
European Countries Involved

Synaptic Dysfunction in Alzheimer Disease

SyDAD

Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between...

Funding Programme
Start Date
End Date
Total Funding
€ 3 846 736
European Countries Involved

Synaptic dysfunction in Neurodegenerative Diseases

SYNDEGEN

Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are...

Funding Programme
Start Date
End Date
Total Funding
€ 3 129 428
European Countries Involved

Targeted small-molecule Stabilisation of Protein-Protein Interactions

TASPPI

The goal of the TASPPI European Training Network (ETN) is the establishment of a highly interdisciplinary research and educational training platform for early stage scientists in the Chemical Life Sciences to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed...

Funding Programme
Start Date
End Date
Total Funding
€ 3 342 323
European Countries Involved

Targeting reconsolidation to strengthen memories in individuals with Mild Cognitive Impairment

MemoMCI

Memory for unique personal experiences (episodic memory) is critical to daily life functioning. This form of long-term memory also displays the largest degree of age-related decline. This condition is accelerated in amnestic mild cognitive impairment (aMCI), which is often the precursor for emerging Alzheimer’s disease (AD). Since AD produces...

Funding Programme
Start Date
End Date
Total Funding
€ 168 277
European Countries Involved

Targeting the brain sigma-1 receptor: A paradigm shift for the treatment of neuro-degenerative disorders

NeuroPa

An increasingly aging population suffering from neurodegenerative diseases represents one of the biggest challenges for Western societies. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease with over 50 million patients worldwide and an estimated cost of 1 trillion euros in 2018. In addition, orphan neurodegenerative diseases...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

The Brain Health Toolbox: Facilitating personalized decision-making for effective dementia prevention

Brain Health Toolbox

Preventing dementia and Alzheimer disease (AD) is a global priority. Previous single-intervention failures stress the critical need for a new multimodal preventive approach in these complex multifactorial conditions. The Brain Health Toolbox is designed to create a seamless continuum from accurate dementia prediction to effective prevention by i)...

Funding Programme
Start Date
End Date
Total Funding
€ 1 498 268
European Countries Involved

The chemistry and physics of RNP granules: how they form, age and cause disease

PhaseAge

Recent studies suggest that defective ribonucleoprotein (RNP) granules and altered RNA processing cause neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). However, defective RNP granules only develop late in life, suggesting that young cells have mechanisms in place to prevent their...

Funding Programme
Start Date
End Date
Total Funding
€ 1 931 303
European Countries Involved

THE DEVELOPMENT OF NOVEL PHOTOSWITCHABLE KINASE INHIBITORS

RET PHOTOSWITCH

The overall research objective of this project is to develop novel photoswitchable kinase inhibitors (PKIs), targeting on REarrange during Transfection (RET) for use in living cells and in zebrafish (Danio rerio). Controlling the action of kinases in a reversible way will have an exceptional potential for investigating signal transduction in...

Funding Programme
Start Date
End Date
Total Funding
€ 185 857
European Countries Involved

The EEG Dementia Index – Fast and Affordable Dementia Diagnosis

BTD

Dementia is a devastating neurodegenerative disease that causes tremendous suffering for patients and their families. The disease’s relentless progression leads to a loss of all mental abilities, making patients completely dependent on constant care and supervision. Even though the disease is incurable, there are treatments available that can...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

The effect of pro-aging and pro-youthful blood factors in normal ageing and Alzheimer’s disease: a multimodal approach

BioALFA

The overall aim of the planned research is to test whether pro-aging and pro-youthful blood factors are associated with cognitive performance and neuroimaging outcomes in normal ageing and in individuals at risk of Alzheimer’s disease (AD), and whether this association is modified by lifestyle habits (e.g. exercise or diet) or genetic factors...

Funding Programme
Start Date
End Date
Total Funding
€ 158 122
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).